Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
|Videos|November 18, 2020
Sharing the Results: ALKS 3831
Author(s)Adam Simmons, MPH
ALKS 3831, if approved by the FDA, could be a promising new treatment option for schizophrenia or bipolar I disorder.
Advertisement
Adam Simmons, MPH, shares results and insights from the Enlightened II study for Alkermes' drug, ALKS 3831.
To read more about ALKS 3831, see
Mr Simmons is the Director of Clinical Program Management at Alkermes.
Advertisement
Related to this article
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
3
FDA Shelves Fast-Track Drug Review Initiative
4
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
5